Table 3 Treatment and outcome between surviving and deceased children with moderate-to-severe ARDS and hematologic or immune-related diseases

MV>7 days

12(54.5)

22(51.2)

0.067

0.796

HFOV, n(%)

4(18.2)

20(46.5)

5.015

0.025

Pulmonary Vasodilators, n(%)

1(4.5)

3(7.0)

/

1.000

Neuromuscular Blocking Agents, n(%)

20(90.9)

37(86.0)

/

0.706

Prone Ventilation, n(%)

3(13.6)

8(18.6)

/

0.737

Systemic Steroid, n(%)

9(40.9)

9(20.9)

2.901

0.089

β-Receptor Agonist, n(%)

9(40.9)

18(41.9)

0.005

0.941

Diuretic, n(%)

17(77.4)

38(88.4)

1.377

0.241

Blood Transfusion, n(%)

9(40.9)

30(69.8)

5.050

0.025

Intravenous Immunoglobulin, n(%)

3(14.3)

14(32.6)

2.698

0.100

CRRT, n (%)

1(4.5)

7(16.3)

/

0.248

Vasopressor, n(%)

12(54.5)

39(90.7)

11.256

0.001

Parenteral Nutrition, n(%)

3(13.6)

5(11.6)

/

1.000

Outcomes

 Intubation time, median and quartile, d

9(3,16)

8(3,16)

0.292

0.770

 Days of PICU, median and quartile, d

13(7,21)

8(4,16)

-1.375

0.169

 Hospital stays, median and quartile, d

20(8,30)

19(10,28)

-0.305

0.760

 MODS, n(%)

4(18.2)

19(44.2)

4.304

0.038